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QUANTIFYING ANTI-CYTOMEGALOVIRUS (CMV) IMMUNITY WITH CMV
ANTIGEN SPECIFIC T CELLS (CASTS) AFTER ALLOGENEIC HEMATOPOI-
ETIC CELL TRANSPLANT (ALLOHCT)
Chen, G.1, Hahn, T.1, Zhang, Y.1, Pan, D.1, Brix, L.2, Ross, M.1,
Liu, H.1, Wallace, P.1, McCarthy, P.1 1Roswell Park Cancer Institute,
Buffalo, NY; 2 Immudex, Copenhagen, Denmark
Reconstitution of CASTs after alloHCT has previously been
quantified using CMV tetramers. We developed an assay for quanti-
fying CASTs using CMV specific MHC multimers (Dextramers,
Immudex, Denmark). CMVDextramers consist of dextran polymers
conjugated to optimized numbers of MHC-CMV peptide and fluo-
rochrome molecules allowing higher avidity binding to CMV spe-
cific T cells. Dextramers were restricted to HLA-A01, -A02, -A03,
-A24 -B07, -B08, and -B35, and were informative in 93% of our pre-
dominantly White (94%) population. Patient blood samples were
prospectively collected pre-alloHCT and day +30, 100, and 365,
and analyzed by flow cytometry for CASTs with CMV Dextramers.
More than 300 CMVDextramer measurements from 89 consecutive
alloHCT patients treated from 2005 - 2011 with. 1 post-alloHCT
CAST measurement were analyzed. CMV reactivation was defined
as the presence of CMV antigen on . 2/50,000 cells, . 1/100,000
cells twice consecutively, or . 1/100,000 cells followed by pre-
emptive CMV therapy. Absence of CMV reactivation was defined
as 0 cells or 1/100,000 cells positive for CMV no more than once
with no anti-CMV treatment. 30/89 (34%) patients reactivated
CMV a median of 40 days (range 23-341) post-alloHCT. None of
37 recipients with undetectable CASTs before allo-HCT reactivated
CMV by day +30 vs. 10/52 (19%) of recipients with detectable
CASTs (p 5 0.005), recapitulating CMV reactivation patterns seen
in recipients with positive CMV serologies. We correlated the num-
ber of CASTs with recipient and donor CMV serology as a surrogate
for anti-CMV immunity. In samples with CD3+ T cells $ 400/mL,
CASTs correlated with recipient CMV serology with 67% sensitiv-
ity and 90% specificity (see Table). Sensitivity may have been lower
than expected due to decreased anti-CMV IgG production second-
ary to chemotherapy and/or increased granularity of flow cytometry
measurements for CASTs. In another analysis, CASTs at day +30
corresponded to positive CMV donor, but not recipient, serology,
and not with CMV reactivation up to day +30, suggesting that the
adoptive transfer of CASTs occurs with alloHCT. Preliminary anal-
yses confirm prior reports of decreased relapse of underlying cancers
after CMV reactivation. Our study suggests that Dextramers may be
used to monitor reconstitution of CMV immunity post-alloHCT,
that they may be a more sensitive test than CMV serology, and
that adoptive transfer of anti-CMV immunity can be quantified.
Table 1. Correlation of CASTs and CMV Serology
Pre-alloHCT Recipient CMV SerologyPre-alloHCT CASTs N (row)Negative (N 5 32) Positive (N 5 31)Undetectable 18 (56%) 2 (6%) 20
Detectable 14 (44%) 29 (94%) 43*All samples with $400 CD3+ T cells191
SAFETY AND PERSISTENCE OF INFUSED CD19-CAR-MODIFIED
MULTIVIRUS SPECIFIC CTLS IN B CELL MALIGNANCIES POST
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Cruz, C.R.Y.1,Micklethwaite, K.P.1, Savoldo, B.1, Ku, S.1, Krance, R.A.1,
Diouf, O.1, Kamble, R.1, Kennedy-Nasser, A.1, Barrett, A.J.2,
Shpall, E.J.3, Heslop, H.E.1, Rooney, C.M.1, Brenner, M.K.1,
Bollard, C.M.1, Dotti, G.1 1Baylor College of Medicine, The Methodist
Hospital, Texas Children’s Hospital, Houston, TX; 2National Institutes
of Health, Bethesda,MD; 3The University of Texas MDAnderson Cancer
Center, Houston, TX
Allogeneic hematopoietic stem cell transplant (HSCT) may in-
crease disease-free survival in patients with high-risk B-cell malig-nancies, but delayed immune reconstitution is associated with viral
infections and disease relapse. We reasoned that a single T-cell plat-
form mediating antiviral and antileukemic activity may benefit these
patients. We prepared CTLs with native specificities directed to-
wards EBV/CMV/adv, then engineered them to express chimeric
antigen receptors (CAR) targeting CD19. We used donor-derived
antigen presenting cells expressing adenovirus antigens & transgenic
CMVpp65. After 3 stimulations, multivirus-specific CTL were
transduced with a retroviral vector encoding CAR-CD19.
Safety: 4 patients (2 relapsed ALL, 2 B-CLL) were infused with 1.5-
3x107 cells/m2 without infusion related toxicity. Patient 2 developed
fever, diarrhea and hypotension 4 weeks post T cells; findings were
consistent with ileitis at a previous site of disease. Gut biopsy showed
abnormal absence of normal & malignant B cells, but significant
levels of CAR-CD19 T cells by qPCR.
Persistence:There was a predictable decline of T cells in peripheral
blood following infusion (undetectable in 1-4 weeks). However, per-
sistence up to 9 weeks after T cell administration is documented by
their presence in disease sites like the gastrointestinal tract (patient 2,
4 weeks post CTL) and the bone marrow (patient 1 and 3, 9 & 4
weeks post CTL respectively).
Anti-tumor activity: Patient 1 (Ph+ ALL) had 4% blasts in the pe-
ripheral blood at time of CTL infusion #1 which cleared within 2
weeks. She received a 2nd infusion 2 months later. She became
bcr-abl-negative but subsequently relapsed and died of progressive
disease 7 months post CTL. Patient 2 with CLL had resolution of
lymphadenopathy within 2 weeks but, following disappearance of
CTLs from peripheral blood, showed evidence of disease progres-
sion 2 months post CTL and died weeks after. Patient 3 with CLL
has had stable disease. Patient 4 (relapsed ALL) responded to the first
CTL infusion with a decrease of blasts (0.5% to 0.3%) 4 days post
CTL. He presented 2 weeks later with 4% blasts, requiring a 2nd
dose of CTLs which decreased disease to 0.2% 2 days post-infusion.
Anti-viral activity:No patient developed viral infections post CTL.
These early results provide evidence of the safety, persistence, and
effectiveness of monoculture CD19CAR trivirus T cells in the treat-
ment of high risk B-cell malignancies post HSCT.192
LONGITUDINAL MONITORING OF IMMUNE RECONSTITUTION AFTER
ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
(PBSCT): IMPACT OF T-CELL DEPLETION OF THE GRAFT
Servais, S.1,2, Hannon, M.2, Daulne, C.2, Gothot, A.1,2, Yves, B.1,2,
Baron, F.1,2 1CHU of Liege, Liege, Belgium; 2University of Liege, Liege,
Belgium
Background: T cell depletion by positive selection of CD34+ cells
of the graft is an effective procedure to reduce the incidence of
graft-versus-host disease following allogeneic PBSCT. However, it
has been suggested that it might impact immune reconstitution.
Patients andMethods:We retrospectively compared the kinetics of
recovery of T, B and NK- cells compartments in 108 adult patients
who had undergone allogeneic PBSCT after high dose conditioning.
Patients had received either CD34-selected (CD34 group, n5 62) or
unmanipulated PBSCT (PBSC group, n5 46). In the CD34 group,
43 of 62 patients had received pre-emptive CD8-depleted donor
lymphocyte infusions (DLI) starting at days 40-60 after PBSCT in
an effort to prevent disease relapse. Circulating cell phenotypes
were studied by flow cytometry on days 28, 40, 60, 80, 100, 180
and 365 after PBSCT, and then yearly thereafter. Median follow-
up was 6 months for both groups (ranging from 1 to 60 months).
We also monitored T-cell repertoire reconstitution on days 100
and 365 post-PBSCT using third complementary region (CDR3)
size spectratyping method (in 9 and 13 patients on days 100 and 2
and 7 patients on days 365, for CD34 andPBSCgroups respectively).
Results: Normal levels of NK (CD3- CD56+) cells and CD8+
(CD3+ CD8+) T cells were reached one month after PBSCT and
were similar in CD34 and PBSC patients. B cell counts attained
lower limit of normal values six months after PBSCT and were sim-
ilar in the CD34 and PBSC groups. CD4+ T-cell reconstitution was
slow in the two groups of patients, with normal values reached only
after 18 to 24 months post-PBSCT. The number of naive CD4+ T
cells (CD4+ CD45RA+) was particularly low throughout the first
Poster Session I S27524 months after transplantation and was lower during the first 120
days in the CD34 group than in the PBSC group (p\0.1, with p
\0.01 on day 40). This difference was more significant after exclud-
ing from the CD34 group patients who had received pre-emptive
DLI (p\0.05, with p\0.01 on days 40 and 60). T-cell repertoire di-
versity was similar in both groups on days 100 and 365 post-PBSCT
(with a median total number for the 24 BV families of 218 bands in
both groups on day 100 post-PBSCT and 223.5 and 236 bands for
the CD34 and PBSC groups respectively on day 365 (p 5 0.67)).
Conclusion: This study suggests that the T-cell depletion of the
graft induced a delayed immune reconstitution for naive CD4+ T
cells after allogeneic PBSCT with high dose conditioning.
193
KINETICS OF IL-7 AND IL-15 LEVELS AFTER ALLOGENEIC PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION (ALLO-PBSCT) FOLLOWING
HIGH-DOSE OR NONMYELOABLATIVE CONDITIONING
De Bock, M., Fillet, M., Merville, M.-P., Gothot, A., Beguin, Y.,
Baron, F. University of Liege, Belgium
Background: Successful allo-PBSCT depends on the recovery of an
adequate immune system, allowing not only to prevent lethal infec-
tions but also to induce immune-mediated graft-versus-tumor ef-
fects. Previous studies have demonstrated that immune recovery
depends mainly on homeostatic peripheral expansion (HPE) of do-
nor T cells contained in the graft the first 3-6 mo. following allo-
PBSCT. IL-7 and IL-15 are the main driving forces of HPE, and
are secreted in response to lymphodepletion. While high-dose con-
ditioning regimens induce generally a profound lymphodepletion,
progressive replacement of host-derived by donor-derived T cells
is the rule after nonmyeloablative conditioning.
Patients and Methods: Data from 106 pts given allo-PBSCT after
high-dose (n 5 36) or low-dose TBI based nonmyeloablative (n 5
70) conditioning were analyzed. Among patients given high-dose
conditioning, 26 patients were given unmanipulated PBSC with
(n 5 24) or without (n 5 2) added ATG and 10 patients received
CD34-selected PBSC.No patient in the nonmyeloablative group re-
ceived ATG orCD-34 selected PBSC. IL-7 plasma and IL-15 serum
levels were measured with a commercial ELISA (R&D Systems,
Minneapolis, MN, USA). Lymphocyte subset counts were analyzed
by flow cytometry.
Results: CD4+ T cell and naive CD4+ T cell counts were lower
(P\0.001) on days 28, 40, 60, 80, 100 and 180 in pts given grafts after
high-dose than in those given nonmyeloablative conditioning. IL-7
levels were higher in pts given high-dose than in those given non-
myeloablative conditioning on days 7, 14, 28, 40, 60, 80 and 100 after
transplantation (p\0.01). Day 28 IL-7 levels were highly correlated
(r\-0.52, P\0.0001) with day 28 counts of T cells, CD4+ T cells,
CD8+ T cells, and naive CD4+ T cells but not with day 28 counts
of NK cells. IL-15 levels were higher in patients given high-dose
than in those given non-myeloablative conditioning on days 7
(p\0.01), 14 (p\0.01), and 28 (p 5 0.055) after transplantation.
There was a correlation between IL-15 levels and day 28 counts of
T cells (r 5 -0.30, P 5 0.002) and NK cells (r 5 -0.38, P 5 0.001).
Conclusions: Our data suggest that the physiology of immune re-
covery and particularly of HPE is significantly different in pts given
high-dose than in those given nonmyeloablative conditioning and
encourage further studies comparing immune recovery and immune
recovery mechanisms in pts given high-dose or nonmyeloablative
conditioning.194
EVIDENCE FOR QUANTITATIVE AND FUNCTIONAL IMMUNE DEVIATION
IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
Kean, L.S.1, Sen, S.1, Felder, M.A.1, Tangpricha, V.1, Adisa, O.1,
Herry, A.J.1, Buchanan, I.2, Ziegler, T.3, Alvarez, J.1, Beus, J.3,
Worthington-White, D.1, Robertson, J.3, George, J.4, Cetron, J.3,
Ofori-Acquah, S.F.1, Osunkwo, I.1 1Aflac Cancer Center and Blood
Disorders Service; 2Morehouse School of Medicine; 3Emory University;
4Sickle Cell Foundation of Georgia
While HSCT is a curative therapy for sickle cell disease (SCD),
SCD patients are at increased risk of graft rejection, especially afternon-myeloablative transplant. To determine whether immune
mechanisms might influence their increased risk of rejection, we
evaluated quantitative and functional immunologic differences be-
tween 23 pediatric SCD patients and 18 age- and ethnicity-matched
controls, using a prospective cross-sectional study design. All pa-
tients and controls were African American and were matched for
gender and age. All patients were at their clinical baseline during
evaluation: no patient was experiencing an acute complication of
SCD. Following informed consent, each subject underwent quanti-
tative flow cytometric immune analysis including enumeration of to-
tal WBC, ANC, ALC, total T cells, B cells and NK cells as well as
CD4+ and CD8+ naive and memory T cell subpopulations. Func-
tional immune assessment was also performed, using multiplexed
analysis of 25 serum cytokines.
Our results provide evidence for significant quantitative and func-
tional immune deviation in SCD patients compared to controls. In
addition to the well-documented increases in total WBC and ANC
(1.9-fold and 1.7-fold compared to controls, respectively, p\0.05),
SCD patients also demonstrated significantly higher total lympho-
cytes, monocytes and both cytotoxic and cytokine-secretingNK cells
(2.9, 2.4, and 2.2-fold compared to controls, p\0.01 for all). Circu-
lating B cells were significantly higher in SCD patients (3.3 fold, p5
0.0005). CirculatingT cells were also increased in SCDpatients, and
this effect was specific to CD4+ T cells (1.7-fold, p 5 0.002). There
was no difference in CD8+ T cells (p5 0.4). The increased CD4+ T
cell count predominantly involved memory CD4+ T subpopula-
tions, with both central and effector memory CD4+ T cells signifi-
cantly increased compared to controls (1.9-fold and 2.5-fold,
respectively, p\ 0.01). SCD patients also showed evidence of func-
tional immune activation at steady state; plasma cytokine analysis re-
vealed higher circulating CXCL10, CCL4 and IL-15 (2.4, 2.1, and
.10 fold compared to controls, p\0.05 for all).
Our results provide strong cellular and molecular evidence for
quantitative and functional immune deviation in SCD patients.
These observations suggest that strategies targeting NK cell, B
cell, and CD4T cell functionmay be required for successful engraft-
ment of SCD patients during non-myeloablative HSCT.
195
SAFETY OF LIPOSOMAL CYTARABINE PROPHYLAXIS IN PEDIATRIC BONE
MARROWTRANSPLANT (BMT) RECIPIENTSWITH ACUTE LEUKEMIA (AL)
AND NON HODGKIN LYMPHOMA (NHL) AT HIGH RISK OF CNS RELAPSE
Hochberg, J., Duffy, D., Harrison, L., Morris, E., Cairo, M.S. New York
Medical College, Valhalla, NY
Liposomal Cytarabine (LC) is a derivative of cytarabine designed
for intrathecal treatment of leukemia/lymphomatous meningitis
(LLM). LC allows for sustained release with prolonged drug expo-
sure of 8 to 14 days in children and adults, respectively. Adult trials
have shown 50mg of LC to be both safe and effective in the treatment
of LLM (Glantz et al, JCO 1999). Bomgaars et al. investigated the
use of LC in children in a phase I dose escalation trial and demon-
strated the maximal tolerated dose to be 35mg and that it was safe,
well tolerated and effective (Bomgaars et al., JCO 2004). However,
there remains a paucity of data on the use of LC prophylaxis to pre-
vent LLM in pediatric allogeneic stem cell (AlloSCT) recipients.
Objective:We report on the safety and tolerability of liposomal cy-
tarabine prior to and following stem cell transplant in pediatric BMT
recipients with AL and NHL.
Methods:Pediatric stem cell recipients with a history of AL orNHL
and high risk of CNS disease received 35mg of LC (\21yr) or 50mg
(.21yr) via lumbar puncture or omaya reservoir pre conditioning
and every 3months for 1-2yrs post stem cell transplant. Patients re-
ceived dexamethasone (0.15mg/kg/dose BID) concomitantly x
5days. There were 8 matched unrelated donor transplants, 9
matched related donor transplants and 3 autologous transplants.
Twelve patients received a TBI (1200 cGy) containing conditioning
regimen. Seven patients received an additional CNS boost of up to
1200 cGy.
Results: To date there have been 21 patients: (12 ALL, 2 AML, 3
Burkitt, 3 DLBCL and 1 T-LL). At the time of transplant, 7 patients
were CR1/PR1, 10 patients CR2 and 4 patients CR3. Patients have
received a total of 46 doses (median 5 1, range 1-12). Median age:
12yr (range 6-22). Mean follow up: 517 days (median 5 294days).
Eight of 21 patients had a history of CNS AL/NHL involvement
